RedHill Biopharma has been granted a patent for a single oral solid dosage form containing two antibiotic agents and a proton pump inhibitor. The capsule includes rifabutin, amoxicillin, and omeprazole, specifically designed for treating H. pylori infections and preventing recurrence. GlobalData’s report on RedHill Biopharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights RedHill Biopharma Ltd - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on RedHill Biopharma, Human telomerase RT biomarker was a key innovation area identified from patents. RedHill Biopharma's grant share as of April 2024 was 57%. Grant share is based on the ratio of number of grants to total number of patents.

Combination capsule for h. pylori treatment

Source: United States Patent and Trademark Office (USPTO). Credit: RedHill Biopharma Ltd

A recently granted patent (Publication Number: US11931463B2) discloses an all-in-one capsule designed for the treatment of H. pylori infection. The capsule contains a combination of rifabutin, amoxicillin, and omeprazole in specific dosages. The omeprazole is in the form of minitablets, with additional minitablets containing a mixture of amoxicillin and rifabutin. These minitablets are coated with a protective enteric coating to ensure effective delivery.

Furthermore, the patent also covers a packaged pharmaceutical preparation containing a specific number of these capsules for a 14-day treatment regimen. The method for treating H. pylori infection involves orally administering a set number of capsules each day at different time points throughout the day for the specified treatment period. The patent also includes variations in the dosages and formulations of the components within the capsule to optimize the treatment efficacy.

To know more about GlobalData’s detailed insights on RedHill Biopharma, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies